Helus Pharma Inc HELP

$6.11 -0.67 (-9.88%)

Valuation

Market cap
487,627,000
Revenue TTM
$0
Net income TTM
$-148,000,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
2,505,200
Avg volume
1,913,400
Day's range
$6.05 – $6.75
Shares out
79,808,000
Stochastic %K
2%
Beta
0.64
Analysts
Strong Buy
Price target
$43.80

Price

Company profile

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company...

Show more

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
908 764 8385
Website
https://www.helus.com
Address
100 King Street West, Suite 5600, Toronto, Canada

Latest news

No headlines yet.